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How to use this Issue...
This issue begins with a composite case study tha s description
is followed by a pretest. The case study is further developed through Challenge questions at the end of each 
section. To fully benefit from this monograph, readers are urged to answer each question when it is presented. 
(Answers to the Pretest and Challenge questions are found on pages 22-24.) The monograph ends with a posttest, 
which can be submitted to ATSDR for continuing medical education (CME) credit or continuing education units 
(CEU). See page 25 for further instructions on how to receive these credits.
The objective of this monograph on arsenic Is to help you:
□  Understand why arsenic remains a hazard of great concern
□  Understand the known factors contributing to arsenic poisoning
□  Assess a patient's environmental or occupational exposure to arsenic
□  Effectively evaluate and manage arsenic-exposed patients
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Arsenic toxicity
A 35-year-old carpenter with peripheral neuropathy and skin lesions
A 35-year-old, fair-skinned male is referred to your clinic for evaluation. His symptoms began approxi­
mately 3 months ago, with the insidious onset of numbness and tingling in his toes and fingertips, 
progressing slowly in the ensuing weeks to involve the feet and hands in a symmetric “stocking-glove" 
fashion. In the past 2 to 3 weeks, the tingling has taken on a progressively painful, burning quality and he 
has noted weakness in gripping tools. No ataxia, dysphagia, visual symptoms, or bowel or bladder incontin­
ence have been noted, and he has not complained of headaches, back or neck pain, or confusion. Except 
as noted, the review of systems is otherwise negative.
The patient’s medical history is remarkable for a flu-like illness approximately 4 months ago characterized 
by 3 to 4 days of fever, cough, diarrhea, and myalgias, which resolved spontaneously.
Further questioning reveals the patient has been a carpenter since completing high school 17 years ago. 
For the last 10 years, he has lived in a rural, wooded area in a home he built. Approximately 10 months 
ago he was married and moved with his wife, an elementary school teacher, into a newly built home on an 
adjacent parcel of land. The patient consumes one to two alcoholic drinks a week, and quit smoking 2 years 
ago after a 15-pack-year history. He takes one multivitamin a day but no prescription medications. Family 
history is unremarkable; his wife, parents, and two younger brothers are in good health.
Neurologic examination reveals diminished proprioception in the hands and feet, with a hyperesthetic 
response to pinprick sensation on the soles. Motor bulk and tone are normal, but there is slight bilateral 
muscular weakness in dorsiflexors of the toes and ankles, wrist extensors, and hand intrinsics. Reflexes 
are absent at the ankles and 1 + at the biceps and knees. Coordination and cranial nerve function are within 
normal limits. Dermatologic examination reveals brown patches of hyperpigmentation, with scattered 
overlying pale spots in and around the axillae, groin, nipples, and neck. The palms and soles show multiple 
hyperkeratotic corn-like elevations 4 to 10 mm in diameter. Three irregularly shaped, sharply demarcated, 
erythematous, scaly plaques, measuring 2 to 3 cm, are noted on the patient’s torso. The remainder of the 
physical examination is normal.
On initial laboratory evaluation, the CBC shows slight macrocytic anemia with hematocrit 35% (normal 
range 40% to 52%), and MCV 111 fL (normal range 80 to 100 fL). White blood cell count is 4.3 x 103/mm3 
(normal range 3.9 to 11.7 x 103/mm3); the differential reveals moderate elevation of eosinophils at 9% 
(normal range 0% to 4%). Occasional basophilic stippling is noted on the peripheral smear. Liver 
transaminases are slightly elevated. BUN, creatinine, and urinalysis are normal.
(a) What problem list is suggested for this patient?
(b) What further investigations would you undertake at this time?
(c) What treatment options would you consider?
Answers to Pretest questions can be found in Challenge answers (2) through (10) on pages 23-24.
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Exposure Pathways
□  Environmental sources of 
arsenic exposure are food, 
water, and air.
□  The relative toxicity of an 
arsenical depends primarily 
on Its chemical type, valence 
state, solubility, and physical 
form.
□  Except In the semiconductor 
Industry, commercial use of 
arsenic has been declining 
since the 1960s.
Arsenic is ubiquitous in the environment. It is released into the 
air by volcanoes, through weathering of arsenic-containing 
minerals and ores, and by commercial or industrial processes. 
In industry, arsenic is a byproduct of the smelting process for 
many metal ores such as lead, gold, zinc, cobalt, and nickel. 
Other potential sources of arsenic exposure are the following:
Natural Sources
Arsenic-containing mineral ores 





Herbicides (weed killers, defoliants)
Fungicides
Cotton desiccants




Fire salts (multicolored flame)
Food
Wine (grapes sprayed with 
arsenic-containing pesticides) 
Tobacco (plants sprayed with 
arsenic-containing pesticides) 
Seafood (especially bivalves, 
certain cold water and bottom- 
feeding finfish, seaweed)
Industrial Processes
Purifying industrial gases 
(removal of sulfur)
Burning fossil fuels 
Burning wood treated with arsenic 
preservatives 
Electronics manufacturing (micro­
wave devices, lasers, light- 
emitting diodes, photoelectric 
cells, semiconductor devices) 
Hardening metal alloys 
Preserving animal hides 
Bronze plating
Clarifying glass and ceramics
Medicináis
Fowler’s solution 
Antiparasitic drugs (carbasone) 
Donovan's solution 
Folk remedies (“Asiatic pill," 
kushtay, yellow root) 
Kelp-containing health foods 
Some naturopathic remedies
Arsenic exists in three common valence states: the metalloid 
(0 oxidation state), arsenite (trivalent state), and arsenate (pen- 
tavalent state). Arsenic-containing compounds vary in their toxi­
city to mammals, depending on valence state, whether it is in the 
inorganic or organic form, physical state-gas, solution, or pow- 
der-and factors such as solubility, particle size, rates of absorp­
tion and elimination, and presence of impurities. With few ex­
ceptions, inorganic arsenic is more toxic than organic arsenic. 
The toxicity of trivalent arsenite is typically greater than that of 
pentavalent arsenate, but little is known about the toxicity of zero 
valent arsenic. Arsine gas (AsHj), used mainly in the microelec­
tronics industry, produces a clinical syndrome very different 
from other arsenic compounds and is the most toxic arsenical.
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Until the 1940s, arsenicals (Salvarsan and Fowler’s solution) 
were widely used in the treatment of various diseases such as 
syphilis and psoriasis. Arsenicals are still used as antiparasitic 
agents in veterinary medicine, and, in some countries, they are 
occasionally used to treat trypanosomiasis and amebiasis in 
humans. Arsenic is also found in some homeopathic and naturo­
pathic preparations, and in folk remedies such as kushtay, a 
tonic used in Asian cultures to cure various sexual disorders.
Commercial use of arsenic peaked in the 1960s and since then 
has steadily declined. As of 1987,74% of the arsenic used in the 
United States is for wood preservation, as compared to less than 
1% for semiconductor manufacture. However, commercial use 
of arsenic in the microelectronics industry is increasing rather 
than declining. Gallium arsenide (GaAs) is used in integral 
components of discrete microwave devices, lasers, light-emit- 
ting diodes, photoelectric chemical cells, and semiconductor 
devices. The use of arsine gas (AsH3) as a dopant in the produc­
tion of semiconductors is also expected to increase, although 
substitutes of lower toxicity such as tributylarsine have recently 
been used. A source of arsine exposure is accidental release 
while manufacturing, transporting, or using the gas. More often, 
however, arsine forms unexpectedly when acid or other reduc­
ing substances are added to arsenic-containing compounds, 
such as metals in which arsenic is a low-level contaminant.
In the general population, the main route of arsenic exposure is 
via ingestion of arsenic-containing food and water. It has been 
estimated that the average daily dietary intake of arsenic by 
adults in the United States is 50 micrograms (ng) per day (range 
of 8 to 104^ig), of which about 18 ^g is inorganic arsenic. Meat, 
fish, and poultry account for 80% of dietary arsenic intake. Fish, 
seafood, and algae also contain high concentrations of arsenic 
in the form of arsenobetaine and arsenocholine, sometimes 
referred to as “fish arsenic.” Fish arsenic has low toxicity to 
humans and is rapidly excreted in urine. Wine made from grapes 
sprayed with arsenic-containing pesticides may have appre­
ciable levels of arsenic. Smokers may also inhale small amounts 
of arsenic as a result of pesticide residue on tobacco leaves.
Well water contaminated by natural sources such as arsenic- 
containing bedrock has been reported to be the cause of arsenic 
toxicity throughout the world, including areas of the United 
States, Germany, Argentina, Chile, Taiwan, and the United 
Kingdom. The areas in the United States with the highest natural 
groundwater concentrations of arsenic are the Southwest, North­
west, Alaska, and other areas near geothermal activity. Ground­
water may also contain elevated concentrations of arsenic due 
to contamination from arsenical pesticide runoff. A study con-
TSDR
ducted in 1970 reported that up to 1% of community water 
supplies in the United States had arsenic concentrations ex­
ceeding 10 ppb. (The U.S. Environmental Protection Agency’s 
[EPA] proposed maximum contaminant level for arsenic in drink­
ing water is 50 parts per billion [ppb].) Both the trivalent and 
pentavalent forms of inorganic arsenic can be found in drinking 
water.
ChaCCen0[
(1) The patient described in the case study lives in the wooded foothills of the Cascade range in 
northwest Washington. His activities have consisted mainly of building new wood frame 
housing, with occasional renovation of older structures. He has used lumber from these projects 
to fuel the stove and fireplaces in his home. Drinking water is obtained from an artesian well 
located on his property.
What are the potential sources of arsenic exposure for the patient described in the case study?
(2) What steps can be undertaken to identify sources of the patient’s arsenic exposure?
Who’s At Risk
The quantity of arsenic released by human activities exceeds 
amounts released from natural sources at least threefold. The 
major sources of arsenic release to the environment are smelt­
ers and pesticides. Besides refinery workers and farmers, other 
workers at increased risk of arsenic exposure include those in 
the industries listed on page 2. People living near smelters and 
other arsenic-emitting facilities also have potential risk of expo­
sure from fugitive airborne emissions and groundwater contami­
nation, 
increased likelihood of 
exposure.
□  Workers in Industries produc­
ing or using arsenic-contain­
ing compounds are poten­
tially at risk.
□  Persons whose water supply 
contains high levels of 
arsenic or those living near 
sources of high ambient air 
levels of arsenic are at
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Arsenic is notorious as a poison because white arsenic (arsenic 
trioxide) has no odor or taste and is available in inexpensive 
products such as pesticides. Most arsenic poisonings are due 
to unintentional ingestion by children. In 1989, EPA instituted a 
phaseout of certain arsenic-containing ant poisons in an effort to 
reduce the incidence of children’s arsenic ingestion.
Burning plywood treated with an arsenate wood preservative in 
a poorly ventilated cabin has been blamed for poisoning a family 
in rural Wisconsin. Green wood or pressed wood treated with 
copper arsenate to prevent mildew is commonly used in marine 
applications, patio decks, and recreational structures for chil­
dren’s playgrounds. Cutting this wood or erosion of the veneer 
may lead to arsenic exposure. Children who play on wood 
structures treated with copper arsenate have increased likeli­
hood of dermal contact or ingestion of the arsenical through 
normal mouthing and play activities.
Methyl transferase enzymes play a necessary role in the methyl- 
ation of arsenic in mammals. The effect of dietary deficiencies 
and genetic variability on methylating capacity may have impor­
tant implications for tissue distribution and individual susceptibil­
ity to arsenic toxicity. Experimental animals fed protein-deficient 
diets while exposed to high levels of arsenic have shown a 
decreased methylating capacity, which has led to increased 
deposits of arsenic in liver, lung, and other organ sites, and 
presumably increased susceptibility to arsenic toxicity.
Arsenic can cross the placenta, exposing the fetus. Significant 
levels of arsenic were found in an infant born 4 days after the 
mother ingested arsenic in a suicide attempt. Increased inci­
dence of spontaneous abortions, infant congenital malforma­
tions, and decreased birth weights have been reported among 
women and their offspring living near a smelter in Sweden; 
however, it is not clear that these events can be ascribed to 
arsenic alone.
Biologic Fate
In humans, soluble forms of ingested arsenic are well absorbed 
from the gastrointestinal tract (60% to 90%). The amount of 
arsenic absorbed by inhalation has not been determined pre­
cisely, but is thought to be in this range. Dermal absorption is 
generally negligible, although toxic systemic effects have re­
sulted from rare occupational accidents where either arsenic 
trichloride or arsenic acid was splashed on workers’ skin. Air­
borne arsenic in the workplace is generally in the form of arsenic 
trioxide. Its particle size determines whether arsenic will reach
□  Arsenic can cross the
placenta, increasing the like' 
lihood of exposure to the 
fetus.
□  The primary routes of arsenic 
entry into the human body 
are ingestion and inhalation; 
percutaneous absorption has 
been reported in occupa­
tional settings.
□  Most tissues rapidly clear 




□  Arsenic undergoes bio- 
methylatlon to less toxic 
metabolites In the liver.
□  Arsenic Is excreted In the 
urine; most of a single, low- 
level dose is excreted within 
a few days after Ingestion.
the lower respiratory tract or be deposited in the upper airways 
and be swallowed after mucociliary clearance. Autopsies per­
formed on retired smelter workers show that arsenic-containing 
particles may remain in the lungs for years.
After absorption through the lungs or gastrointestinal tract, 
arsenic initially accumulates in the liver, spleen, kidney, lungs, 
and gastrointestinal tract. Clearance from these tissues, how­
ever, is rapid. Two to 4 weeks after exposure ceases, most of the 
arsenic remaining in the body is found in keratin-rich tissues 
such as skin, hair, and nails, and to a lesser extent, in bones and 
teeth.
Oxidation-reduction reactions result in some interconversion of 
arsenate (+5) and arsenite (+3) in vivo. A portion of the arsenite 
is then biomethyiated, predominantly in the liver, to methylar- 
sonic acid and dimethylarsinic acid. The methylation process 
may represent detoxification because the metabolites exert less 
acute toxicity in experimental lethality studies.
Methylation efficiency in humans decreases with increasing 
arsenic dose. When the methylating capacity of the liver is 
exceeded, exposure to excess levels of inorganic arsenic results 
in increased retention of arsenic in soft tissues. Cell culture 
studies suggest that the methylating process is inducible since 
pretreatment with small amounts of arsenic over a prolonged 
period increases the methylating efficiency when a large dose is 
subsequently applied. Fish arsenic is apparently not biotrans­
formed in vivo, but is rapidly excreted unchanged in the urine.
Arsenic is excreted primarily through the kidneys. After low- 
level exposure to inorganic arsenic, most of the urinary arsenic 
is present as methylated metabolites. Other less important 
routes of elimination of inorganic arsenic include sweat, skin 
desquamation, and incorporation into hair and nails.
After a single intravenous injection of radiolabeled trivalent 
inorganic arsenic in human volunteers, most of the arseniccleared 
through urinary excretion within 2 days, although a small amount 
of arsenic was found in the urine up to 2 weeks later. The biologic 
half-life of ingested fish arsenic in humans is estimated to be less 
than 20 hours, with total clearance in approximately 48 hours. 
Because arsenic is rapidly cleared from the blood, blood levels 
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(3) Analysis of a spot sample of the patient's urine revealed 60001ig/L (normal is less than 50 \ig/L) 
as total arsenic. What factors could be responsible for this le vet, and what additional history would 
you elicit?
Physiologic Effects
Two mechanisms of arsenic toxicity that may lead to injury in a 
number of organ systems have been described. It is believed 
that arsenic’s overt toxicity results primarily from its inhibition of 
critical suifhydryl-containing enzymes; trivalent arsenite is par­
ticularly potent in this regard. Pentavalent arsenate, however, 
can competitively substitute for phosphate in many biochemical 
reactions. Replacing the stable phosphate anion with the less 
stable arsenate anion leads to rapid hydrolysis of the high- 
energy bonds in compounds such as ATP. Loss of these bonds 
results in the loss of energy needed for critical steps in cellular 
metabolism.
Arsine gas poisoning results in a considerably different syn­
drome from that caused by other forms of arsenic. After inhala­
tion, arsine rapidly fixes to red ceils, producing irreversible cell 
membrane damage. At low levels arsine is a potent hemolysin, 
causing dose-dependent intravascular hemolysis. At high levels 
arsine produces direct multisystem cytotoxicity.
Because it targets ubiquitous 
enzyme reactions, arsenic 
affects nearly all organ 
systems.
Unlike other arsenlcals, 
arsine gas causes a hemo­
lytic syndrome.
Arsenic is strongly associ­
ated with lung and skin can­
cers and may cause other 
cancers.
Gastrointestinal, Hepatic, and Renal Effects
The gastrointestinal effects of arsenic are generally the result of 
ingestion; however, Gl effects may also occur after heavy expo­
sure by other routes. The fundamental Gl lesion appears to be 
increased permeability of the small blood vessels, leading to 
fluid loss and hypotension. Extensive inflammation and necro­
sis of the mucosa and submucosa of the stomach and intestine
Gastrointestinal effects are 
seen primarily after arsenic 
ingestion, and less often 
after inhalation or dermal ab­
sorption.
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□  Acuta arsenic toxicity may bs 
associated with hepatic ne­
crosis and elevated levels of 
liver enzymes.
□  Arsenic is capable of causing 
acute renal failure, as well as 
chronic renal insufficiency.
□  Acute arsenic poisoning may 
cause both diffuse capillary 
leak and cardiomyopathy, 
resulting In shock.
□  Long-term Ingestion of 
arsenic In drinking water has 
resulted in pronounced 
peripheral vascular changes.
may occur and progress to perforation of the gut wall. A hemor­
rhagic gastroenteritis may develop, with bloody diarrhea as a 
presenting symptom.
Arsenic intoxication may also result in hepatic effects, including 
elevated liver enzyme levels. Autopsies of Japanese children 
poisoned with arsenic-contaminated milk revealed hepatic hemor­
rhagic necrosis and fatty degeneration of the liver. Chronic ar­
senic ingestion may lead to noncirrhotic portal hypertension. 
Case reports have also linked chronic high-level arsenic expo­
sure with hepatic angiosarcoma, a rare form of cancer.
The systemic toxicity occurring in severe acute arsenic poison­
ing may be accompanied by acute renal tubular necrosis. Glom­
erular damage can result in proteinuria. Cortical necrosis has 
also been reported.
Cardiovascular Effects
The extent of cardiovascular injury may vary with age, arsenic 
dose, and individual susceptibility. In acute arsenic poisoning- 
usually suicide attempts-the fundamental lesion, diffuse capil­
lary leak, leads to generalized vasodilation, transudation of 
plasma, hypotension, and shock. Delayed cardiomyopathy may 
also develop. Myocardial damage can result in a variety of 
electrocardiographic findings including broadening of the QRS 
complex, prolongation of the QT interval, ST depression, flatten­
ing of T waves, and atypical, multifocal ventricular tachycardia.
Epidemiologic evidence indicates that chronic arsenic exposure 
is associated with vasospasm and peripheral vascular insuffi­
ciency. Gangrene of the extremities, known as Blackfoot disease, 
has been associated with drinking arsenic-contaminated well 
water in Taiwan, where the prevalence of the disease increased 
with increasing age and well-water arsenic concentration (10 to 
1820 ppb). Persons with Blackfoot disease also had a higher 
incidence of arsenic-induced skin cancer. However, investiga­
tors believe other vasoactive substances found in the water may 
have been contributory.
Raynaud’s phenomenon and acrocyanosis resulted from con­
tamination of the city’s drinking water supply in Antofagasta, 
Chile, at arsenic concentrations ranging from 20 to 400 ppb. 
Autopsies of Antofagasta children exposed to arsenic revealed 
fibrous thickening of small- and medium-sized arteries and myo­
cardial hypertrophy. Similar vascular disorders, as well as ab­
normal electrocardiographs (ECGs), have been noted in vine­




Peripheral neuropathy is a common complication of arsenic 
poisoning. It is predominantly due to destruction of axonal cylin­
ders (axonopathy). Early electrodiagnostic testing may reveal 
features indistinguishable from Guillain-Barr6 syndrome (acute 
inflammatory demyelinating polyneuropathy). The neuropathy 
evolves into a more classic sensorimotor distal axonopathy. 
Sensory effects, particularly painful dysesthesia, occur earlier 
and may predominate in moderate poisoning, whereas ascending 
weakness and paralysis may predominate in severe poisoning. 
However, cranial nerves are rarely affected, even in severe poi­
soning. Both acute and chronic arsenic intoxication may be as­
sociated with encephalopathy.
Recovery from neuropathy induced by chronic exposure to 
arsenic compounds is generally slow, sometimes taking years, 
and complete recovery may not occur. Follow-up studies of 
Japanese children who chronically consumed arsenic-contami­
nated milk revealed an increased incidence of severe hearing 
loss, mental retardation, epilepsy, and other brain damage. 
Hearing loss as a sequelae of acute or chronic arsenic intoxica­
tion has not been confirmed by other case reports or epidemio­
logic studies.
Dermal Effects
The skin lesions occurring most frequently in arsenic-exposed 
humans are hyperpigmentation, hyperkeratosis, and skin can­
cer. Patchy hyperpigmentation, a pathologic hallmark of chronic 
exposure, may be found anywhere on the body, but occurs 
particularly on the eyelids, temples, axillae, neck, nipples, and 
groin. The classic appearance of the dark brown patches with 
scattered pale spots is sometimes described as “raindrops on a 
dusty road.” In severe cases, the pigmentation extends broadly 
over the chest, back, and abdomen. Pigment changes have 
been observed in populations chronically consuming drinking 
water containing 400 ppb or more arsenic.
Arsenical hyperkeratosis occurs most frequently on the palms 
and soles. Keratoses usually appear as small corn-like eleva­
tions, 0.4 to 1 centimeter in diameter. In most cases, arsenical 
keratoses show little cellular atypia and may remain morphologi­
cally benign for decades. In other cases, cells develop marked 
atypia (precancerous) and appear indistinguishable from Bowen’s 
disease, which is an in situ squamous cell carcinoma discussed 
in Carcinogenic Effects below.
□  Arsenic-exposed patient* 
develop destruction of axonal 
cylinders leading to periph­
eral neuropathy.
□  Pigment changes and palmo- 
plantar hyperkeratosis are 
characteristic of chronic 
arsenic exposure.
□  Benign arsenical keratoses 
may progress to malignancy.
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□  Inhalation of high concentra­
tions of arssnlc compounds 
produces irritation of the 
respiratory mucosa.
□  Lung cancer has been 
reported In populations of 
arsenic-exposed smelter 
workers.
□  Bone marrow depression may 
result from acute or chronic 
arsenic Intoxication and may 
Initially manifest as pancyto­
penia.
□  The carcinogenicity of
arsenic In humans has been 
established, but no animal 
model has been developed.
□  Latency for skin cancer 
associated with ingestion of 
arsenic may be 3 to 4 dec­
ades, while the noncarcino- 
genlc skin effects typically 
develop several years after 
exposure.
Respiratory Effects
Smelter workers experiencing prolonged exposures to high 
concentrations of airborne arsenic at levels rarely found today 
had inflammatory and erosive lesions of the respiratory mucosa, 
including nasal septum perforation. Lung cancer has been asso­
ciated with chronic arsenic exposure in smelter workers and 
pesticide workers.
Hematopoietic Effects
Both acute and chronic arsenic poisoning may affect the hema­
topoietic system. A reversible bone marrow depression with 
pancytopenia may occur. Anemia and leukopenia are common 
in chronic arsenic toxicity and are often accompanied by throm­
bocytopenia and mild eosinophiiia. The anemia may be norm- 
ocytic or macrocytic, and basophilic stippling may be noted on 
peripheral blood smear.
Carcinogenic Effects
in humans, chronic arsenic ingestion is strongly associated with 
an increased risk of skin cancer, and may cause cancers of the 
lung, liver, bladder, kidney, and colon; chronic inhalation of 
arsenicals has been closely linked with lung cancer. The precise 
mechanism of arsenic-related carcinogenicity is unknown. Arsenic 
causes chromosomal damage in cultured mammalian cells, 
which may be mediated by arsenic’s effects on the enzymatic 
processes involved in DNA replication and repair. Paradoxically, 
cancer associated with arsenic exposure has not been produced 
in experimental animals.
Skin Cancer
An increased risk of skin cancer in humans is associated with 
chronic exposure to inorganic arsenic in medication, contami­
nated water, and the workplace. Arsenic-induced skin cancer is 
frequently characterized by lesions over the entire body, mostly 
in unexposed areas such as the trunk, palms, and soles. More 
than one type of skin cancer may occur in a patient. Most of the 
Taiwanese who developed skin cancer in association with in­
gested arsenic-contaminated drinking water had multiple cancer 
types. The most commonly reported types, in order of decreas­
ing frequency, were intraepidermal carcinomas (Bowen’s dis­
ease), squamous cell carcinomas, basal cell carcinomas, and 
“combined forms.” Seventy-two percent of the Taiwanese with 




Some hyperkeratinized lesions can develop into intraepidermal 
carcinoma, which may ultimately become invasive. The lesions 
are sharply demarcated, round or irregular plaques that tend to 
enlarge; they may vary in size from 1 mm to more than 10 cm. 
Arsenical basal cell carcinomas most often arise from normal 
tissue, are almost always multiple, and frequently occur on the 
trunk. The superficial spreading lesions are red, scaly, atrophic, 
and are often indistinguishable from Bowen’s disease by clinical 
examination. Arsenic-associated squamous cell carcinomas are 
distinguished from uv-induced squamous cell carcinomas by 
their tendency to occur on the extremities (especially palms and 
soles) and trunk rather than on sun-exposed areas such as the 
head and neck.
Epidemiologic studies indicate that a dose-response relation­
ship exists between the level of arsenic in drinking water and the 
prevalence of skin cancers in the exposed population. Excessive 
mortality rates due to arsenic-induced skin cancer have also 
been observed in vineyard workers with dermal and inhalation 
exposure.
Lung Cancer
An association between lung cancer and occupational exposure 
to inorganic arsenic has been confirmed in several epidemio­
logic studies. A higher risk of lung cancer was found among 
workers exposed predominantly to arsenic trioxide in smelters 
and to pentavalent arsenical pesticides in other settings. Nei­
ther concomitant exposure to sulfur dioxide nor cigarette smoke 
were determined to be essential co-factors in these studies.
In arsenic-exposed workers, 
there Is a systematic gradient 
In lung cancer mortality 
rates, depending upon 
duration and Intensity of 
exposure.
Clinical Evaluation
History and Physical Examination
The source of exposure is identified in fewer than 50% of arsenic □  The source of arsenic expo- 
poisonings; however, a careful history and physical examination sure cannot be Identified In
may improve these statistics. Because arsenic intoxication may many cases,
affect multiple organ systems, a complete physical examination 
is imperative. In chronic ingestion, particular clues to arsenic
11
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□  In acute arsenic poisoning, 
death is usually due to 
cardiovascular collapse and 
hypovolemic shock.
□  Onset of peripheral neuropa' 
thy may be delayed several 
weeks after the Initial toxic 
insult.
□  Mees lines may be visible in 
the fingernails several 
months after acute arsenic 
exposure.
poisoning may be provided by dermatologie and neurologic 
findings. The medical history should include the following:
occupational history 
diet
residential history (proximity to smelters, other industry, and 
hazardous waste sites) 
smoking history 
condition of household pets
hobbies (including use of pesticides or herbicides in farming or 
gardening)
medications (including folk or naturopathic medications) 
source of drinking water
home heating methods (wood-burning stoves and fireplaces)
Signs and Symptoms 
Acute Exposure
Acute arsenic poisoning rarely occurs in the workplace today; it 
usually results from unintentional ingestion, suicide, or homi­
cide. The fatal dose of ingested arsenic in humans is difficult to 
determine from case reports and depends upon many factors 
(e.g., solubility, valence state, etc.). The minimal lethal dose is 
in the range of 50 to 300 milligrams. The signs and symptoms of 
acute arsenic poisoning include the following:
Gastrointestinal Cardiovascular and Respiratory
severe abdominal pain hypotension, shock
nausea and vomiting ventricular arrhythmia













garlic odor on the breath 
delayed appearance of 
Mees lines
Hepatic and Renal
elevated liver enzymes 
hematuria, oliguria, proteinuria, 










As a result of inorganic arsenic's direct toxicity to the epithelial 
cells of the gastrointestinal tract and its systemic enzyme inhibi­
tion, profound gastroenteritis, sometimes with hemorrhage, can 
occur within minutes to hours after acute ingestion. Symptoms 
may last for several days. Difficulty in swallowing, abdominal 
pain, vomiting, diarrhea, and dehydration may result. However, 
in subacute poisoning the onset of milder Gl symptoms may be 
so insidious that the possibility of arsenic intoxication is over­
looked.
Arsenic has deleterious effects on the heart and peripheral 
vascular system. Capillary dilation with fluid leakage and third 
spacing may cause severe hypovolemia and hypotension. Cardiac 
manifestations have included cardiomyopathy, ventricular dys­
rhythmias (atypical ventricular tachycardia and ventricular fibril­
lation), and congestive heart failure.
A delayed sensorimotor peripheral neuropathy may occur after 
acute arsenic poisoning. Symptoms are initially sensory and 
may begin 2 to 4 weeks after resolution of the first signs of 
intoxication resulting from ingestion (shock or gastroenteritis). 
Commonly reported initial symptoms include numbness, tingling 
and “pins and needles" sensations in the hands and feet in a 
symmetrical “stocking-glove” distribution, and muscular tender­
ness in the extremities. Clinical involvement spans the spectrum 
from mild paresthesia with preserved ambulation to distal weak­
ness, quadriplegia, and, in rare instances, respiratory muscle 
insufficiency.
Other findings in acute arsenic poisoning may include fever and 
facial edema. Several months after poisoning, transverse white 
striae (pale bands) on the nails called Mees lines (or Aldrich- 
Mees lines) may be seen, reflecting transient disruption of nail 
plate growth during acute poisoning. In episodes of multiple 
acute exposures, several Mees lines may occur within a single 
nail. In some cases, the distance of the lines from the nail bed 
may be used to roughly gauge the date of the poisoning episode.
Respiratory tract irritation (cough, laryngitis, mild bronchitis, and 
dyspnea) may result from acute exposure to airborne arsenic 
dust. Nasal septum perforation, as well as conjunctivitis and 
dermatitis, have also been reported.
The toxicity of arsine gas is quite different from toxicity of other 
arsenicals, requiring different emphases in the medical history, 
physical examination, and patient management. Arsine is a 
powerful hemolytic poison in both acute and chronic exposures. 
The clinical signs of hemolysis may not appear for up to 24 hours 
after acute exposure, thereby obscuring the relationship be­
tween exposure and effect. Initial symptoms of arsine poisoning 
may include headache, nausea, abdominal pain, and hematuria.
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□  Neuropathy may be the first 
sign of chronic arsenic 
toxicity.
□  Hyperpigmentation and 
hyperkeratosis are delayed 
hallmarks of chronic arsenic 
exposure.
□  Anemia often accompanies 
skin lesions In patients 
chronically poisoned by 
arsenic.
□  Lung cancer and skin cancer 
are serious long-term con­
cerns in cases of chronic 
arsenic exposure.
Chronic Exposure
Skin lesions and peripheral neuropathy are the most suggestive 
effects of arsenic ingestion, and their presence should result in 
an aggressive search for this etiology. Neuropathy can occur 
insidiously in chronic toxicity without other apparent symptoms. 
However, careful evaluation usually reveals signs of multiorgan 
and multisystem involvement such as anemia, leukopenia, skin 
changes, or elevated liver function tests.
Manifestations of chronic arsenic ingestion depend on both the 
intensity and duration of exposure. An intense exposure of sev­
eral milligrams a day results in anemia, neuropathy, and hepa- 
totoxicity within a few weeks to months. Hematologic and neu­
rologic signs may occur after a similar latency period. Skin 
lesions, however, take longer to manifest (3 to 7 years for pig­
mentation changes and keratoses; up to 40 years for skin 
cancer) and may occur after lower doses than those causing 
neuropathy or anemia.
Chronic arsenic dust inhalation may be accompanied by upper 
respiratory symptoms, nasal perforation, and lung cancer; how­
ever, since permissible workplace arsenic levels have been 
lowered, these conditions are rarely encountered in workers.
j i ^ 0
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(4) What findings are suggestive of arsenic intoxication in the patient described in the case study?
(5) What conditions other than arsenic intoxication should be considered in the differential diagnosis 




Clinical diagnosis of arsenic intoxication is often difficult be­
cause both acute and chronic poisoning present a wide spec­
trum of signs and symptoms, which are largely dependent upon 
route of exposure, chemical form, dose, and time elapsed since 
exposure. In many cases, the patient or person providing the 
history may suppress information, or the source of exposure 
may not be apparent. By integrating laboratory results with 
history and clinical findings, it is often possible to confirm a 
diagnosis.
Immediately after patient stabilization, laboratory tests should 
be performed to obtain baseline values, with periodic monitoring 
as indicated. Because urinary levels of arsenic may drop rapidly 
in the first 24-48 hours after acute exposure, a urine specimen 
for arsenic analysis should be obtained promptly. Depending on 
the patient’s clinical state, tests may include the following:
General Tests
CBC with peripheral smear 
Liver function tests 
BUN and creatinine 
Urinalysis
Nerve conduction velocity (if peripheral neurologic 
symptoms are present)
ECG




Some arsenic compounds, particularly those of low solubility, 
are radiopaque, and if ingested may be visible on an abdominal 
radiograph.
Direct Biologic Indicators
The key diagnostic laboratory test for recent exposure is urinary 
arsenic measurement. The best specimen is a 24-hour urine 
collection, although spot urine specimens can be helpful in an 
emergency. Normal total urinary arsenic values are less than 
50 ng arsenic per liter (As/L) in the absence of consumption of 
seafood in the past 48 hours; values in excess of 200 |xg As/L are 
considered abnormal. Test results may be reported in |xg arsenic 
per gram creatinine to avoid effects due to variation in urine 
output. Fish arsenic can significantly increase total urinary 
arsenic levels; therefore, it may be prudent to take a dietary 
history of the previous 48 hours or repeat the urinary arsenic test 
in 2 or 3 days. Human volunteers with an average pretest urinary
□  Early clinical diagnosis of 
arsenic toxicity Is often diffi­
cult; a key laboratory test in 
recent exposures Is urinary 
arsenic excretion.
□  When total urinary arsenic is 
measured, it Is important to 
inquire about recent diet.
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arsenic level of 30 ng/L were given lobster tail for lunch. Four 
hours after eating, they had an average urinary level of 1300 jig 
As/L. These values decreased to pretest levels within 48 hours 
after ingestion. Arsenic blood levels, normally less than 7 ng/dL, 
are less useful than urinary arsenic measurements in following 
the clinical course of an acute poisoning case because of the 
rapid clearance of arsenic from the blood.
Long after urine levels have returned to baseline, the arsenic 
content of hair and nails may be the only clue of arsenic expo­
sure. However, because the arsenic content of hair and nails 
may be increased by external contamination, caution must be 
exercised in using the arsenic content of these specimens to 
diagnose arsenic intoxication.
Indirect Biologic Indicators
The standard tests listed above will aid in evaluating the status 
of an arsenic-exposed patient. The CBC can provide evidence 
of arsenic-induced anemia, leukopenia, thrombocytopenia, or 
eosinophilia. Although basophilic stippling on the peripheral 
smear does not confirm arsenic poisoning, it is consistent with 
the diagnosis. Liver transaminases are frequently elevated in 
acute and chronic arsenic exposure and can help confirm clinical 
suspicion. If arsenic neuropathy is suspected, nerve conduction 
velocity tests should be performed. Such tests may show a 
decrease in amplitude initially, as well as slowed conduction. 
Skin lesions in patients with chronic arsenic exposure may 
require biopsy to rule out skin cancer.
(6) What further medical work-up is indicated for the patient described in the case study?
(7) What does the presence of palmar-plantar keratosis suggest about the time course of the 
patient's arsenic exposure?
(8) Who else in the case study is at risk for exposure to arsenic?
(9) A urine specimen from the wife of the patient was found to contain total arsenic at a concentration 
of 300 \ig/L, and a sample of the wife’s hair contained 150 ppm arsenic. Compare this to the 
patient's 6000 \ig/L urinary arsenic level and 100 ppm arsenic in the hair. The wife has no signs 





Patients with suspected acute arsenic poisoning generally re­
quire rapid stabilization with fluid and electrolyte replacement in 
an intensive-care setting. Aggressive intravenous fluid replace­
ment therapy may be life-saving in severe acute poisoning. 
Gastric lavage may be useful soon after an acute ingestion to 
prevent further absorption. The efficacy of activated charcoal is 
controversial, but its administration together with a cathartic 
(such as sorbitol) is frequently recommended. If profuse diar­
rhea is present, cathartics should be withheld. Hemodialysis 
may be beneficial in a patient with concomitant renal failure.
Dimercaprol (2,3-dimercaptopropanol, also known as British 
anti-Lewisite or BAL) is the most frequently recommended 
chelating agent for arsenic. Parenteral dimercaprol is often 
administered intramuscularly at an initial dose of 3 to 5 milli­
grams per kilogram of body weight every 4 hours for 2 days, and 
every 6 hours on the third day, then every 12 hours thereafter for 
10 days, unless an orally administered chelating agent is substi­
tuted. Data supporting duration of treatment are limited, and 
regimens may warrant adjustment. If acute renal insufficiency 
develops, hemodialysis may be of value in removing the dimer- 
caprol-arsenic complex. Since certain dimercaproi-metal com­
plexes are less stable in acid media, alkalization of the urine has 
been recommended to protect the kidneys during therapy. All 
known chelating agents have adverse side effects and should be 
used with caution.
In animal models, the efficacy of chelation therapy generally 
declines as the time elapsed since exposure increases. If pa­
tients are treated within several hours after arsenic ingestion, 
chelation is likely to be beneficial. Therefore, even if arsenic 
ingestion is only suspected, it may be valuable to give one or two 
doses of dimercaprol while awaiting confirmation since side 
effects usually are not noxious enough to outweigh benefits.
Another potential chelating agent is dimercaptosuccinic acid 
(DMSA), a water-soluble analog of dimercaprol currently under 
investigation. Hypotension, nausea, vomiting, and diarrhea early 
in the course of arsenic poisoning may hamper administration 
and subsequent absorption of oral DMSA. The use of D-penicil- 
lamine as an oral chelating agent is controversial.
□  Gut decontamination and 
hemodynamic stabilization 
ars key factors in the initial 
management of acute arsenic 
Intoxication.
□  Chelating agents adminis­
tered within hours of arsenic 
absorption may successfully 




Therapy in arsine gas poisoning is supportive and is primarily 
aimed at maintaining renal function. Exchange transfusion with 
donor cells may be necessary to replace the patient’s hemolyzed 
red cells.
If the source of arsenic exposure has not been determined, it 
may be inadvisable to discharge patients until the health depart­
ment or other appropriate officials have inspected their environ­
ment. Unless such inspection locates and eliminates the source 
of exposure, the patient may be at risk for further arsenic 
intoxication.
Chronic Exposure
Removal from the source of 
poisoning and supportive 
measures are used to 
manage a patient chronically 
poisoned with arsenic.
Available evidence does not 
support the routine use of 
chelation therapy for patients 
with an established arsenic 
neuropathy.
Identification and removal of the toxic source and supportive 
measures are primary concerns for the treatment of chronically 
exposed patients. Studies suggest that the use of vitamin A 
analogs (retinoids) may be useful in treating precancerous ar­
senical dermatoses. Recovery from chronic arsenic toxicity, 
particularly from the resulting peripheral neuropathy, may take 
months and may not be complete. An established arsenical 
neuropathy is not improved by chelation therapy. The value of 
chelation therapy in preventing an incipient neuropathy has 






The Occupational Safety and Health Administration (OSHA) 
mandates permissible limits for occupational exposures. The 
permissible exposure limit (PEL) for arsenic can be no greater 
than 10 micrograms of Inorganic arsenic per cubic meter of air 
(10 ng/m3), averaged over any 8-hour period for a 40-hour work­
week. The recommended exposure limit (REL) set by the 
National Institute for Occupational Safety and Health (NIOSH), 
is 2 ng/m3 for a 15-mlnute ceiling, based on classification of 
arsenic as a potential human carcinogen (Table 1).
There Is little agreement 
between governmental regu­
lations and the recommenda­
tions of advisory organiza­
tions on the acceptable levels 
of arsenic In the workplace.
Table 1. Standards and regulations for inorganic arsenic
Agency * Focus Level Comments
ACGIH Air-Workplace 200 ng/m3 Advisory; 8-hour TWA^





Regulation; PEL over 8-hour 
workday
EPA Air-Environment N/A Under review
Water 50 ppb Regulation; maximum 
contaminant level in drinking 
water
FDA Food 0.5-2 ppm Regulation; applies to animals 
treated with veterinary drugs
* ACGIH -  American Conference of Governmental Industrial Hygienists; EPA -  Environmental 
Protection Agency; FDA « Food and Drug Administration; NIOSH = National Institute for 
Occupational Safety and Health; OSHA = Occupational Safety and Health Administration; 
WHO « World Health Organization
^TWA (Time-Weighted Average) = time-weighted average concentration for a normal 8-hour 
workday and 40-hour workweek to which nearly all workers may be repeatedly exposed.
&
PEL (Permissible Exposure Limit) 
a worker may be exposed.
= highest level averaged over an 8-hour workday, to which
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Q EPA limits ths «missions 
from copper smelters, glass 
manufacturing plants, and 
other arsenic-using facilities; 
however, no ambient air 
standard for arsenic currently 
exists.
□  EPA has recently proposed 
50 ppb as the allowable level 
for arsenic in drinking water.
□  FDA currently has no toler­
ance levels for arsenic in 
food, except for the bypro­
ducts of animals treated with 
veterinary drugs.
□  In 1989, household ant killers 
containing sodium arsenate 
were banned because of 




Arsenic is listed by EPA, under authorization of the Clean Air Act, 
as a hazardous air pollutant, defined as a substance that may 
cause an increased mortality or serious illness in humans after 
significant exposure. In 1986, EPA promulgated the National 
Emissions Standards for Hazardous Air Pollutants for three 
stationary source categories known to emit organic arsenic: 
primary copper smelters, glass manufacturing plants, and arse­
nic plants. However, there is currently no ambient air standard 
for arsenic.
Drinking Water
The EPA Office of Drinking Water has proposed a MCL for 
arsenic in drinking water of 50 ppb. The World Health Organization 
(WHO) also recommends a drinking water guideline of 50 ppb, 
which is considered to be a tenfold safety margin above levels 
known to have caused skin cancer in Taiwan.
Food
The U.S. Food and Drug Administration (FDA) has established 
tolerance levels for arsenic in byproducts of animals treated with 
veterinary drugs. These permissible levels range from 0.5 ppm 
in eggs and uncooked edible tissues of chickens and turkeys to 
2 ppm in certain uncooked edible byproducts of swine.
Pesticides
In 1989, EPA began to phase out household ant poisons contain­
ing sodium arsenate because of the danger of ingestion by small 
children. The EPA Office of Pesticide Programs (OPP) has 
restricted the use of inorganic arsenic to pressure-treating wood. 
It has proposed cancellation of all registered uses of inorganic 
arsenic for nonwood preservative purposes except for the use of 
calcium arsenate as a turf herbicide, lead arsenate as a grape­
fruit growth regulator, sodium arsenite as a grape fungicide, and 





Hindmarsh JT, McCurdy RF. Clinical and environmental aspects of arsenic toxicity. CRC Crit Rev Clin Lab 
Sci 1986;23:315-47.
Ishinishi N, Tsuchiya K, Vahter M, Fowler BA. Arsenic. In: Handbook on the toxicology of metals. 2nd ed. 
Amsterdam: Elsevier, 1986:43-83.
Pershagan G. Sources of exposure and biological effects of arsenic. In: IARC Science Publication, 71. 
Lyon, France: IARC, 1986:45-61.
Schoolmeester WL, White DR. Arsenic poisoning. South Med J 1980;2:198-208.
Carcinogenicity
Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer: a reanalysis. Am 
J Epidemiol 1987;125:929-38.
Falk H, Caldwell GG, Ishak KG, et al. Arsenic-related hepatic angiosarcoma. Am J Ind Med 1981 ;2:43- 
50.
Yeh S. Skin cancer in chronic arsenicism. Hum Pathol 1973;4(4):469-85.
Yeh S, How SW, Lin CS. Arsenical cancer of skin-histologic study with special reference to Bowen’s 
disease. Cancer 1968;21(2):312-339.
Neurologic Effects
Donofrio PD, Wilbourne J, Albers JW, Rogers L, Salanga V, Greenberg HS. Acute arsenic intoxication 
presenting as Guillain-Barr6-like syndrome. Muscle Nerve 1987;10:114-20.
Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to arsenic. J Neurol Sci 
1977;32:437-51.
Murphy MJ, Lyon LW, Taylor JW. Subacute arsenic neuropathy: clinical and electrophysiological 




Datta DV. Arsenic and non-cirrhotic portal hypertension. Lancet 1976;1:433.
Franklin M, Bean W, Harden RC. Fowler's solution as an etiologic agent in cirrhosis. Am J Med Sci 
1950;219:589-96.
Hematologic Effects
Kyle RA, Pease GL. Hematologic aspects of arsenic intoxication. N Engl J Med 1965;273:18-23.
Selzer PM, Ancel MA. Chronic arsenic poisoning masquerading as pernicious anemia. West J Med 
1983;139:219-20.
Drinking Water as Source of Exposure
Armstrong CW, Stroube RB, Rubio T, et al. Outbreak of fatal arsenic poisoning caused by contaminated 
drinking water. Arch Environ Health 1984;39:276-9.
Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, 
lung, and liver in Blackfoot disease endemic area in Taiwan. Br J Cancer 1986;53:399-405.
Valentine JL, Kang HK, Spivey G. Arsenic levels in human blood, urine, and hair in response to exposure 
via drinking water. Environ Res 1979;20:24-32.
Related Government Documents
Agency for Toxic Substances and Disease Registry. Toxicological profile for arsenic. Atlanta: US 
Department of Health and Human Services, Public Health Service, 1989. NTIS report no. PB/89/ 
185706/AS.
Environmental Protection Agency. Health assessment document for inorganic arsenic. Research Triangle 
Park, NC: US Environmental Protection Agency, Environmental Criteria and Assessment Office, 1984. 
Report no. EPA/600/8-83/021F.
Environmental Protection Agency. Special report on ingested inorganic arsenic: skin cancer; nutritional 
essentiality. Washington, DC: US Environmental Protection Agency, Risk Assessment Forum, 1988. 
Report no. EPA/625/3-87/013.
Answers to Pretest and Challenge Questions
(1) The patient’s drinking water, obtained from an artesian well, may contain elevated levels of arsenic due 
to leaching from natural mineral deposits in the surrounding bedrock. This phenomenon has been 
noted sporadically throughout the United States, including the Northwest. The patient’s employment 
in carpentry and home construction may place him in contact with arsenic-containing wood preserva­
tives used to treat lumber. Exposure may potentially occur percutaneously in the course of repeatedly 
handling moist, freshly treated lumber or via inhalation or ingestion of wood dust liberated during 
sawing. Ingestion or inhalation of ash or flue gas created during burning of arsenic-treated wood in 
his home fireplace or wood stove may also be a source of household arsenic exposure.
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(2) A sample of the patient's well water can be sent for arsenic analysis. Lists of qualified laboratories may 
be obtained from the county or state health department. The patient should be questioned about his 
use of arsenic-treated wood and wood preservatives: arsenic content may be listed on product 
containers or on Material Safety Data Sheets available from the supplier. The supplier should also 
indicate whether purchased lumber has been treated with arsenical wood preservatives. The patient 
should be questioned regarding possible use of arsenic-containing pesticides. In any case of sus­
pected arsenic intoxication, the physician should consider the possibility of intentional poisoning and 
notify social agencies, if appropriate.
(3) Because nontoxic trimethylated organic arsenic (arsenobetaine or arsenocholine) ingested in a 
seafood meal may markedly elevate total arsenic levels, the patient should be questioned about 
ingestion of seafood within the past 2 days. If seafood has been ingested, laboratory speciation of the 
urinary arsenic can eliminate the contribution of arsenobetaine or arsenocholine. However, given the 
patient’s clinical presentation, exposure to toxic inorganic arsenic is likely.
In this case, speciation reveals inorganic arsenic present at 1700 ng/L, monomethyl arsonic acid at 
2200 iig/L, and dimethyl arsenic acid at 2100 iig/L, confirming that the patient has sustained inorganic 
arsenic exposure. Since most laboratories do not provide speciation, an alternative approach to 
interpreting a high urinary arsenic concentration (>500 to 1000 ng/L) if seafood ingestion is a possible 
factor would be to repeat the measurement with a new urine sample 48 to 96 hours after complete 
avoidance of seafood. The trimethylated fish arsenic should be completely cleared by that time, but 
the metabolites of inorganic arsenic, which have slower clearance, should still be present at elevated 
levels.
(4) The patient’s problem list includes peripheral neuropathy, hyperpigmentation and hyperkeratotic skin 
lesions, macrocytic anemia, and liver transaminase elevation. The neurologic, dermatologic, and he­
matologic abnormalities are highly suggestive of chronic arsenic intoxication. He has a characteristic 
stocking-glove peripheral neuropathy, with predominantly painful sensory symptoms, in the absence 
of apparent cranial nerve or central nervous system dysfunction. His skin displays hyperpigmentation 
and palmar-plantar hyperkeratoses characteristic of chronic arsenic ingestion. Consistent laboratory 
findings include a CBC and peripheral blood smear displaying macrocytic anemia, relative eosino- 
philia, and occasional basophilic stippling, and a chemistry panel revealing slight elevation in liver 
transaminases.
(5) Guillain-Barr6 syndrome is a primarily motor neuropathy that may begin shortly after a viral infection 
or immunization. Although the patient’s neurological complaints began 1 month after a flu-like illness, 
examination failed to reveal the characteristic rapid tempo and motor predominance of Guillain-Barr6 
syndrome. Chronic alcoholism may be associated with sensorimotor peripheral neuropathy, macro­
cytic anemia, and liver transaminase elevation, but cerebellar ataxia and other findings such as 
hepatomegaly and telangiectasia are usually also present with alcoholism. Thallium intoxication may 
also result in a sensorimotor peripheral neuropathy. Other diagnostic considerations include paraneo­
plastic syndromes, particularly those associated with lung cancer, diabetes mellitus, and certain 
chronic inflammatory neuropathies.
(6) The patient’s urine should be screened for the presence of arsenic and thallium using either a 24-hour 
urine collection or a first void morning specimen. A chest X ray should be examined for occult 
malignancy. Referral for electromyography and nerve conduction studies may be useful to further 
characterize the peripheral neuropathy and to establish an objective baseline for follow-up measure­
ment. Dermatologic assessment of the patient's skin lesions, possibly including skin biopsy, is indi­
cated to evaluate for cancer or to characterize a precancerous state. The possibility of diabetes 
mellitus can be investigated by measuring a fasting blood glucose.
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(7) Arsenic-induced skin changes generally result from chronic arsenic exposure and have a latency of 
several years. Hyperpigmentation typically precedes hyperkeratoses, which in turn precede dermal 
neoplasms. The presence of both hyperpigmentation and palmar-plantar keratoses in the patient 
suggests that his arsenic exposure began at least 3 years ago, before consumption of drinking water 
from his current well. Since he resided on nearby property for 10 years, the well at that location should 
also be suspected of containing high levels of arsenic.
(8) The patient’s wife, who resides with the patient and may consume the same well water, is at risk for 
chronic arsenic poisoning. Residents in the surrounding geographical area, who may also be obtaining 
water from artesian wells should be considered at risk. Former area residents who consumed arsenic 
chronically before moving away constitute a third group potentially at risk for delayed development of 
arsenic-associated disease.
(9) A careful history reveals that the wife, unlike the patient, consumed the well water infrequently, 
preferring instead to drink bottled soft drinks and juices. Before moving with her husband 10 months 
ago, she resided in a metropolitan area geographically remote from the present site, where the water 
was not obtained from wells. Thus, because her arsenic ingestion was markedly lower and of shorter 
duration than her husband’s, she has not yet developed signs or symptoms of chronic arsenic 
intoxication.
Both the patient and his wife use the arsenic-containing well water for showers and baths. The sub­
stantial amount of arsenic in the wife’s hair likely reflects external contamination from this source. The 
arsenic content of the husband's hair is elevated from a combination of external contamination and 
internal incorporation into the growing hair. The relative contribution from endogenous and exogenous 
sources cannot be distinguished through bulk hair analysis.
(10) Immediate cessation of consumption of arsenic-containing well water is the essential first step. 
Because the utility of chelating agents in reversing or improving the patient's arsenic-related 
peripheral neuropathy, anemia, and palmar-plantar keratoses is unestablished, chelation treatment 
cannot be routinely recommended. Analgesics and/or certain tricyclic antidepressants have been 
reported to be beneficial for the painful dysesthesias associated with peripheral neuropathies. 
Because some reports indicate that vitamin A analogs (retinoids) may be valuable in the treatment of 
precancerous arsenical keratoses, referral to a dermatologist for consideration of this treatment is 
indicated. The patient will remain at risk for the delayed appearance of arsenic-related skin cancer 
and merits regular, long-term dermatologie follow-up.
(11) Because of the likelihood that other wells in the area contain elevated levels of arsenic, public health 
intervention may be necessary to prevent other cases of hazardous arsenic exposure.
Sources of Information
More information on the adverse effects of arsenic and the treatment and management of arsenic-exposed 
persons can be obtained from ATSDR, your state and local health departments, and university medical 
centers. Case Studies in Environmental Medicine: Arsenic Toxicity is one of a series. For other publications 
in this series, please use the order form on the back cover. For clinical inquiries, contact ATSDR, Division 




Continuing education credit is available to health professionals who use this monograph and complete the 
posttest. The criterion for awarding CME credits and CEUs is a posttest score of 70% or better.
The Centers for Disease Control (CDC) is accredited by the Accreditation Council for Continuing Medical 
Education (ACCME) to sponsorcontinuing medical education for physicians, and by the Council on the Continuing 
Education Unit (CCEU) to sponsor continuing education units for other health professionals.
The Agency for Toxic Substances and Disease Registry, in joint sponsorship with CDC, is offering 1 credit hour 
of continuing medical education (CME) credit in category 1 of the Physician's Recognition Award of the American 
Medical Association and 0.1 hour of continuing education units (CEU) for other health professionals upon 
completion of this monograph.
This program has been reviewed and is acceptable for 1 prescribed hour by the American Academy of Family 
Physicians (term of approval: through March 16,1991). For specific information, please consult the AAFP Office 
of Continuing Medical Education.
The American College of Emergency Physicians (ACEP) has approved this program for 1 hour of ACEP Category 
1 credit.
The American Osteopathic Association (AOA) has approved this program for 1 credit hour of Category 2-B AOA- 
CME credit.
To receive continuing education credit (CME or CEUs), complete the Posttest on page 26 in the manner shown 
in the sample question below. Circle all correct answers.
Which of the following is known to precipitate migraine headaches?
After you have finished the Posttest, please transfer your answers to the answer sheet on the inside back cover 
and complete the evaluation on the lower half of that page. Fold, staple, and mail the back cover to Continuing 
Education Coordinator, Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 
1600 Clifton Road, Atlanta, GA 30333. Your confidential test score will be returned with an indication of where 
the correct answers can be found in the text. Validation of earned CME credit and CEUs will also be forwarded 
to participants, and their names, if requested, will be placed on the mailing list to receive other issues in the Case 









Circle all correct answers and transfer your answers to page 27.












3. Clinical signs that may occur in persons with cases of chronic arsenic poisoning include
a. encephalopathy




4. In the diagnosis of arsenic poisoning
a. neurologic findings may be the first diagnostic clue
b. hyperpigmentation is associated with chronic intoxication
c. acute hemolysis may indicate arsine gas poisoning
d. Mees lines may be visible a day after acute exposure
e. lung and skin cancer may occur
5. Findings that may be encountered in arsenic intoxication include





6. Measures that may be necessary in the treatment of acute arsenic poisoning include
a. hemodialysis if renal failure occurs
b. parenteral chelation therapy with dimercaprol (BAL)
c. fluid replacement therapy with hemodynamic monitoring
d. hemoperfusion using an ion exchange resin
e. oral chelation therapy with Prussian blue
7. Some of the more likely activities for exposure to arsenic are
a. using an indoor firing range
b. eating seafood
c. manufacturing silicon wafers or computer chips
d. sewing textiles
e. preparing blue prints
8. Which of the following statements are true?
a. pentavalent arsenic is excreted primarily in feces
b. arsenic undergoes methylation in vivo
c. spinach contains a high amount of arsenic
d. trivalent arsenic cannot cross either the blood-brain or placental barriers
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If you wish CME credits or CEUs, please indicate your answers to the Posttest questions on page 26 by circling 
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requested on the reverse side. Tear off this last page, fold, staple, and mail to Continuing Education Coordinator, 
Agency forToxic Substances and Disease Registry, Division of Health Education, E33,1600 Clifton Road, Atlanta, 
GA 30333.
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Please complete the following evaluation by circling your response.
1. Was the breadth of information in this issue sufficient for your needs?
Yes No Undecided
2. Was the amount of detail appropriate?
Too technical Just right Not technical enough
3. As a result of reading this issue, will you now ask patients more questions regarding possible 
environmental exposures?
Yes No Undecided Not applicable
4. Would you recommend this issue to your colleagues?
Yes No Undecided
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□  methylene chloride
□  polyaromatic hydrocarbons (PAHs)
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